Stigmasterol and barasertib target cuproptosis-related prognostic model for the synergistic treatment of breast cancer.

Abstract

Abstract Background Breast cancer (BRCA) has a high incidence and a poor prognosis. Cuproptosis is a crucial regulator of carcinogenesis and tumor progression. However, it has not been reported how cuproptosis in BRCA patients is treated using Chinese and Western medicines. Methods This study investigated how cuproptosis is used to diagnose and treat BRCA. A cuproptosis prognostic model was constructed using a bioinformatics approach. We used LASSO to establish a prognostic model associated with cuproptosis, and demonstrated the reliability of the model with survival analysis. Results CIBERSORT analysis showed that the prognostic model was associated with immune infiltration. An interesting finding from the CellMiner database analysis revealed a high correlation between the risk score and Barasertib. According to network pharmacology and molecular docking analysis, stigmasterol, an active ingredient of Curcuma longa L., may target the gene ADAM9 in the prognostic model. The combination of drugs confirmed that stigmasterol and barasertib had a significant synergistic effect on BRCA cells. Conclusion Our study provides a potential strategy for treating cuproptosis in combination with Chinese and Western medicines for BRCA.